HISTONE DEACETYLASE INHIBITOR INDUCED ANTI-MYELOMA ACTIVITY IS MEDIATED PRINCIPALLY VIA CLASS I DEACETYLASE INHIBITION

被引：0
|
作者：
Mithraprabhu, S. [1 ]
Kalff, A. [2 ]
Quach, H. [3 ]
Khong, T. [4 ]
Andrew, A. [5 ,6 ]
机构：
[1] Monash Univ, Alfred Hlth, Melbourne, Vic, Australia
[2] Alfred Hosp, Malignant Hematol & Stem Cell Transplantat, Melbourne, Vic, Australia
[3] Monash Univ, Dept Clin Hematol, Clayton, Vic, Australia
[4] Monash Univ, Alfred Hosp, Australian Ctr Blood Dis, Melbourne, Vic, Australia
[5] Monash Univ, Alfred Hosp, ACBD, MH&SCT, Melbourne, Vic, Australia
[6] Monash Univ, Alfred Hosp, DCH, Melbourne, Vic, Australia
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0260
引用
收藏
页码：104 / 105
页数：2
相关论文
共 50 条
  • [21] Class I histone deacetylase activity is required for proliferation of renal epithelial cells
    Tang, Jinhua
    Yan, Yanli
    Zhao, Ting C.
    Bayliss, George
    Yan, Haidong
    Zhuang, Shougang
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2013, 305 (03) : F244 - F254
  • [22] Class I histone deacetylase inhibitor Entinostat sensitises prostate cancer cells to radiation
    McCullough, B.
    Manley, J.
    McDade, S.
    Wilson, M. LaBonte
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S330 - S331
  • [23] Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor
    Chutake, Yogesh K.
    Lam, Christina C.
    Costello, Whitney N.
    Anderson, Michael P.
    Bidichandani, Sanjay I.
    NUCLEIC ACIDS RESEARCH, 2016, 44 (11) : 5095 - 5104
  • [24] CLASS I HISTONE DEACETYLASE INHIBITION REDUCES SUSTAINED ATRIAL FIBRILLATION AND REMODELING IN DOGS
    Seki, Mitsuru
    Powers, Jeffery
    Huang, Jianhe
    LaCanna, Ryan
    Varkas, Christine
    Arkles, Jeffrey
    Cooper, Joshua
    Berretta, Remus
    Recchia, Fabio
    Patel, Vickas
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 671 - 671
  • [25] Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure
    Gallo, Pasquale
    Latronico, Michael V. G.
    Gallo, Paolo
    Grimaldi, Serena
    Borgia, Francesco
    Todaro, Matilde
    Jones, Philip
    Gallinari, Paola
    De Francesco, Raffaele
    Ciliberto, Gennaro
    Steinkuehler, Christian
    Esposito, Giovanni
    Condorelli, Gianluigi
    CARDIOVASCULAR RESEARCH, 2008, 80 (03) : 416 - 424
  • [26] Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat
    Zenz, Tamara
    Jenke, Robert
    Oliinyk, Denys
    Noske, Sandra
    Thieme, Rene
    Kahl, Tim
    Gockel, Ines
    Meier-Rosar, Florian
    Aigner, Achim
    Buech, Thomas R. H.
    NEOPLASIA, 2025, 60
  • [27] PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes
    Smalley, Joshua P.
    Adams, Grace E.
    Millard, Christopher J.
    Song, Yun
    Norris, James K. S.
    Schwabe, John W. R.
    Cowley, Shaun Michael
    Hodgkinson, James T.
    CHEMICAL COMMUNICATIONS, 2020, 56 (32) : 4476 - 4479
  • [28] Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics
    Gupta, Rohan
    Ambasta, Rashmi K.
    Kumar, Pravir
    LIFE SCIENCES, 2020, 256
  • [29] Class I Histone Deacetylase Inhibition Modulates Metalloproteinase Expression and Blocks Cytokine-Induced Cartilage Degradation
    Culley, Kirsty L.
    Hui, Wang
    Barter, Matt J.
    Davidson, Rose K.
    Swingler, Tracey E.
    Destrument, Auriane P. M.
    Scott, Jenny L.
    Donell, Simon T.
    Fenwick, Steve
    Rowan, Andrew D.
    Young, David A.
    Clark, Ian M.
    ARTHRITIS AND RHEUMATISM, 2013, 65 (07): : 1822 - 1830
  • [30] Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue
    Acharya, MR
    Figg, WD
    CANCER BIOLOGY & THERAPY, 2004, 3 (08) : 719 - 720
12345